Mirador Capital Partners LP Raises Position in Pfizer Inc. (NYSE:PFE)

Mirador Capital Partners LP grew its position in shares of Pfizer Inc. (NYSE:PFE) by 4.5% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 35,968 shares of the biopharmaceutical company’s stock after purchasing an additional 1,552 shares during the period. Mirador Capital Partners LP’s holdings in Pfizer were worth $954,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in PFE. IFS Advisors LLC grew its holdings in shares of Pfizer by 787.7% in the fourth quarter. IFS Advisors LLC now owns 3,693 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 3,277 shares during the period. Winch Advisory Services LLC boosted its holdings in shares of Pfizer by 6.5% in the fourth quarter. Winch Advisory Services LLC now owns 17,265 shares of the biopharmaceutical company’s stock worth $458,000 after buying an additional 1,053 shares during the last quarter. Roble Belko & Company Inc raised its position in Pfizer by 49.7% in the fourth quarter. Roble Belko & Company Inc now owns 5,801 shares of the biopharmaceutical company’s stock worth $154,000 after acquiring an additional 1,926 shares during the period. Advisors Management Group Inc. ADV grew its position in shares of Pfizer by 1.4% during the 4th quarter. Advisors Management Group Inc. ADV now owns 192,185 shares of the biopharmaceutical company’s stock valued at $5,099,000 after acquiring an additional 2,706 shares during the period. Finally, ARS Wealth Advisors Group LLC increased its stake in shares of Pfizer by 4.9% in the 4th quarter. ARS Wealth Advisors Group LLC now owns 24,967 shares of the biopharmaceutical company’s stock worth $662,000 after purchasing an additional 1,176 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Trading Down 0.2 %

Shares of PFE stock opened at $26.17 on Thursday. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a 50-day moving average of $26.13 and a two-hundred day moving average of $28.03. The firm has a market cap of $148.31 billion, a PE ratio of 35.37, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company’s revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.17) earnings per share. On average, analysts predict that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.57%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

Analysts Set New Price Targets

Several analysts have issued reports on PFE shares. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. Citigroup started coverage on shares of Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target for the company. Sanford C. Bernstein began coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Finally, StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.